National Institute for Health and Care Excellence (NICE) guidance recommends acetylcholinesterase inhibitors (AChEIs) for the management of mild to moderate AD, and the addition of memantine alone or with AChEIs to manage moderate/severe AD.3 However, while these may result in small improvements in cognitive and behavioural symptoms, they do not modify disease progression. This evidence concerns the gene ACHE and Alzheimer disease.